Business · India Bureau
Biocon shares gain despite sharp Q2 profit slump
Biocon's stock price recovered nearly 6% following the release of second-quarter results, even as the company reported a 52% decline in consolidated net profit. The biosimilars and active pharmaceutical ingredients manufacturer's profit plunged to ₹41 crore despite modest revenue growth.
LSN India ·
Biocon Limited shares climbed close to 6% in recent trading sessions, defying expectations set by disappointing quarterly earnings. The Bangalore-headquartered pharmaceutical company reported consolidated net profit of ₹41 crore for the second quarter of the financial year, representing a sharp 52% year-on-year contraction.
The profit decline came despite revenue from operations growing by 2% during the same period, indicating margin pressures across the company's business divisions. The mixed results reflect ongoing headwinds in both its biosimilars and active pharmaceutical ingredients segments.
The stock had earlier touched a 52-week low of ₹318.40 on the National Stock Exchange, weighing on investor sentiment ahead of the earnings announcement. Market analysts attributed the recent price recovery to technical buying and potential value recognition among investors following the sharp sell-off.
Biocon, which operates in biosimilars, specialty generics, and contract research and manufacturing services, continues to navigate competitive pressures in key markets including the United States and Europe. The company's management will likely face investor questions regarding its profit recovery trajectory and cost management strategies in upcoming guidance updates.